This allowed for the first time the identification of mutations associated with acquired resistance to ICB and shown loss of function mutation in IFN signaling (Janus kinase-1 and 2) in two patients and beta-2-microglobulin (B2M) in a third patient in ICB resistant cancer lesions (157). Here, JAK1 is linked to cancer.